🔎 Trials Near Me

Akèy › Leksemi mieloïd egi › Oregon › Portland

Etid klinik pou Leksemi mieloïd egi nan Portland, OR

25 etid pou Leksemi mieloïd egi ap chèche patisipan nan sit nan ak bò kote Portland (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.

Tèks ofisyèl etid la (Anglè)

Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

Ap rekriteFaz 2
  • Providence Portland Medical Center, Portland
  • Providence Saint Vincent Medical Center, Portland
Laj 18 ak plis · Tout sèks · Mizajou Oct 5, 2026 · NCT05564390

Ruxolitinib With Azacitidine Maintenance for the Treatment of Patients With Acute Myeloid Leukemia Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation

Ap rekriteFaz 1
  • OHSU Knight Cancer Institute, Portland
Laj 18 ak plis · Tout sèks · Mizajou Oct 5, 2026 · NCT07548983

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Ap rekriteEtid obsèvasyonVolontè an sante akeyi
  • Providence Portland Medical Center, Portland
  • Providence Saint Vincent Medical Center, Portland
  • Providence Willamette Falls Medical Center, Oregon City · 12 mi lwen
Laj 40 a 75 · Tout sèks · Mizajou Oct 2, 2026 · NCT05334069

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

Ap rekriteFaz 2
  • Providence Portland Medical Center, Portland
  • Providence Saint Vincent Medical Center, Portland
Laj 18 a 59 · Tout sèks · Mizajou Sep 28, 2026 · NCT05554393

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

Ap rekriteFaz 3
  • Providence Portland Medical Center, Portland
  • Providence Oncology and Hematology Care Clinic Westside, Portland
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06852222

Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Ap rekriteFaz 1
  • OHSU Knight Cancer Institute, Portland
Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2026 · NCT03874052

Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

Ap rekriteFaz 2
  • Providence Portland Medical Center, Portland
  • Providence Saint Vincent Medical Center, Portland
Laj 18 a 59 · Tout sèks · Mizajou Sep 22, 2026 · NCT05554406

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

Ap rekriteFaz 2
  • Providence Portland Medical Center, Portland
  • Providence Saint Vincent Medical Center, Portland
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT06317649

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

Ap rekriteFaz 3
  • Legacy Emanuel Children's Hospital, Portland
  • Oregon Health and Science University, Portland
6 Months – 21 Years · Tout sèks · Mizajou Sep 17, 2026 · NCT04293562

A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

Ap rekriteFaz 1/2
  • Oregon Health & Science University, Portland
30 Days · Tout sèks · Mizajou Sep 16, 2026 · NCT04065399

Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies

Ap rekriteFaz 1/2
  • Oregon Health and Science University, Portland
Laj 18 ak plis · Tout sèks · Mizajou Sep 14, 2026 · NCT03471260

Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML

Ap rekriteFaz 3
  • US-Portland OR-OHSU, Portland
Laj 18 ak plis · Tout sèks · Mizajou Sep 2, 2026 · NCT06652438

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

Ap rekriteFaz 1/2
  • Legacy Emanuel Children's Hospital, Portland
  • Oregon Health and Science University, Portland
Jiska laj 22 · Tout sèks · Mizajou Aug 25, 2026 · NCT04726241

Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)

Ap rekriteFaz 3
  • Doernbecher Children's Hospital, Portland
29 Days – 21 Years · Tout sèks · Mizajou Aug 24, 2026 · NCT05183035

Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT

Ap rekriteFaz 3
  • Oregon Health & Science University (OHSU) - Knight Cancer Institute, Portland
Laj 18 a 75 · Tout sèks · Mizajou Jul 17, 2026 · NCT05429632

Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia

Ap rekriteFaz 1
  • OHSU Knight Cancer Institute, Portland
Laj 18 ak plis · Tout sèks · Mizajou Jul 14, 2026 · NCT04659616

Induction and Consolidation With Fludarabine, Cytarabine, Idarubicin, and Venetoclax for the Treatment of Acute Myeloid Leukemia

Ap rekriteFaz 2
  • OHSU Knight Cancer Institute, Portland
Laj 18 a 65 · Tout sèks · Mizajou Jul 13, 2026 · NCT07228273

Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

Ap rekriteFaz 2
  • Oregon Health and Science University, Portland
Laj 18 ak plis · Tout sèks · Mizajou Jul 7, 2026 · NCT07216443

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

Ap rekriteEtid obsèvasyon
  • Oregon Health & Science University/Doernbecher Children's Hospital, Portland
Tout laj · Tout sèks · Mizajou Jul 6, 2026 · NCT01351545

Iadademstat in Combination With Azacitidine and Venetoclax in Treating Newly Diagnosed Acute Myeloid Leukemia

Ap rekriteFaz 1
  • OHSU Knight Cancer Institute, Portland
Laj 18 ak plis · Tout sèks · Mizajou Jun 30, 2026 · NCT06357182

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

Ap rekriteFaz 2/3
  • Oregon Health and Science University, Portland
Laj 18 ak plis · Tout sèks · Mizajou Apr 30, 2026 · NCT04256317

A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML)

Ap rekriteFaz 1
  • OHSU, Portland
Laj 18 ak plis · Tout sèks · Mizajou Feb 9, 2026 · NCT06950034

Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia

Ap rekriteVolontè an sante akeyi
  • Oregon Health & Science University, Portland
Laj 18 a 120 · Tout sèks · Mizajou Jul 25, 2025 · NCT05237258

Etid Leksemi mieloïd egi nan lòt vil

Lòt etid nan Portland

Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.